CSIMarket
 
908 Devices inc   (NASDAQ: MASS)
 
Price: $10.6700 $-0.06 -0.559%
Day's High: $10.800000190734863 Week Perf: -3 %
Day's Low: $ 10.49 30 Day Perf: 33.21 %
Volume (M): 246,214 52 Wk High: $ 11.25
Volume (M$): $ 0 52 Wk Avg: $7.26
Open: $10.80 52 Wk Low: $5.03



 Market Capitalization (Millions $) 393
 Shares Outstanding (Millions) 37
 Employees 172
 Revenues (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 1

Business Description


We have created a revolutionary line of portable and desktop mass spectrometry, or Mass Spec, equipment for the point-of-need market. We make the exceptional analytical capability of Mass Spec available in devices that are substantially smaller and more accessible than traditional laboratory equipment by leveraging our patented platform technology. Our Mass Spec devices are employed at the point of need to investigate unknown and unseen materials and deliver immediate, actionable solutions to some of the most essential challenges in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent sectors.
We create simplified measurement devices that our customers can use as accurate tools where-and-when their work needs to be done, rather than overly complex and centralized analytical instrumentation. We believe the insights and answers our devices provide will accelerate workflows, reduce costs, and offer transformational opportunities for our end users.

Since the launch of our first device, we have sold more than 1,900 handheld and desktop devices to over 450 customers in 42 countries, including all 20 of the top 20 pharmaceutical companies by revenue, as well as numerous domestic and foreign government agencies and leading academic institutions.
Mass Spec is the gold-standard analytical technology for laboratory-based molecular analysis and can identify and quantify sample components via molecular weight measurements. Mass Spec is highly regarded for its ability to provide an extraordinarily detailed analysis of a wide variety of samples -- from small molecules to large complex proteins. While Mass Spec is an extremely powerful analytical tool, conventional Mass Spec instruments are very large, expensive, and highly complex, which has profoundly bottlenecked market opportunities and relegated them to the equivalent of mainframe computers in central facilities. We are seeking to reimagine where Mass Spec technology can be used if it is sufficiently small in size, low in cost, and simple to operate.

Our proprietary Mass Spec platform relies on extreme miniaturization of the core of Mass Spec -- the ion trap and its vacuum system. Using semiconductor microfabrication techniques, we design and produce components that are more than a thousand fold smaller in volume when compared with most laboratory Mass Spec instruments and costs only dollars to manufacture. The vacuum system alone in a typical laboratory instrument weighs hundreds of pounds and requires several hundred watts of power, 24 hours per day, 365 days per year. Our miniaturized vacuum system weighs less than a pound, and our Mass Spec in total requires less power than a 20-watt LED light bulb. These landmark proprietary advances have enabled the first truly handheld Mass Spec devices and compact desktops.

Sample preparation and separation can be a painfully slow hours-long process, and we have invested heavily in the development of microfluidic sample preparation and microscale separation technologies to reduce preparation and separation time from hours to minutes. The size of a business card, our microfluidic capillary-electrophoresis, or CE, chip has demonstrated world-class performance and speed in separating everything from small molecules such as metabolites and drugs, to biopharmaceutical proteins, antibodies, and oligonucleotides.
Lastly, it is imperative that a point-of-need solution is operable by the widest possible user base. We have an industry-leading software automation and machine learning team comprised of five members, each with advanced scientific degrees, who have collective experience working on 30 commercial product launches and have won numerous research and innovation awards. They have applied advanced software automation and machine learning techniques to both control the hardware in our devices and interpret the incredibly rich and complex data streaming off of them. It is common for expert data interpretation from a laboratory Mass Spec instrument to take hours or days -- we can provide answers immediately to maximize value to the customer in critical-to-life applications where minutes matter.


   Company Address: 44 Third Avenue Burlington 1803 MA
   Company Phone Number: 254-1500   Stock Exchange / Ticker: NASDAQ MASS


Customers Net Income grew by MASS's Customers Net Profit Margin fell to

2.83 %

18.71 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TMO   -1.85%    
A        0.08% 
BRKR        1.81% 
CERT        4.15% 
DBMM   -20%    
DHR   -0.72%    
• View Complete Report
   



Business Update

908 Devices Inc. and Getinge Pioneering Continuous Monitoring in Bioprocessing Amidst Sector Challenges

Published Thu, Dec 19 2024 1:47 PM UTC

In the dynamically evolving landscape of bioprocessing, innovation is not just an advantage; it s a necessity. The recent partnership between 908 Devices Inc. and Getinge marks a significant advancement in the automation of bioreactor management, enhancing the capabilities of researchers and scientists working on cell cultures. Innovative Collaboration in Bioprocessing Techn...

Business Update

908 Devices Advances XplorIR Analyzer Amidst Competitive Challenges

Published Tue, Jun 18 2024 12:47 PM UTC

In the ever-evolving landscape of chemical analysis, 908 Devices Inc. (Nasdaq: MASS), a leader in developing handheld and desktop devices for chemical identification and analysis, has carved out a significant niche for itself. The company s latest move seeks to bolster its position further through technological enhancements to one of its key products, the XplorIR portable an...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 6.92
Price to Sales (Expected) -
Price to Book 2.93
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.79
Working Capital Ratio 4.82
Leverage Ratio (MRQ) 0.39
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.98 $
Revenues (TTM) 1.54 $
Cash Flow (TTM) -
Cash 3.03 $
Book Value 3.64 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 330,023
Net Income per Employee (TTM) -209,703
Receivable Turnover Ratio (TTM) 5.91
Inventory Turnover Ratio (TTM) 1.89
Asset Turnover Ratio (TTM) 0.3

Profitability Ratios Current
Gross Margin (MRQ) 53.42 %
Operating Margin (MRQ) -100.02 %
Net Margin (MRQ) -92.8 %
Net Cash Flow Margin (MRQ) -22.93 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



908 Devices Inc's Segments
United States    82.27 % of total Revenue
Europe Middle East and Africa    8.76 % of total Revenue
Asia Pacific    4.5 % of total Revenue
Americas other    8.34 % of total Revenue
United States federal and defense    25.3 % of total Revenue
United States State authorities and local municipalities    52.59 % of total Revenue
Rest of world national and provincial organizations    21.08 % of total Revenue
Global pharmaceutical industrial and other    4.91 % of total Revenue
Handheld product and service revenue    98.97 % of total Revenue
OEM and funded partnership revenue    4.91 % of total Revenue
Device sales revenue    72.66 % of total Revenue
Recurring revenue    31.21 % of total Revenue
Single reportable segment    103.87 % of total Revenue

  908 Devices Inc Outlook

On January 15 2025 the 908 Devices Inc provided following guidance

nn908 Devices Inc. Provides Preliminary Financial Results for Q4 and Full Year 2024nn

nBoston – January 15, 2025n – 908 Devices Inc. (NASDAQ: MASS), a leader in the development of specialized handheld and desktop devices for chemical analysis, has released its preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2024.

The company anticipates that its revenue for the fourth quarter of 2024 will reach approximately $17.2 million. This represents a notable growth of around 20% compared to the $14.4 million recorded in the same period of 2023. This upward trajectory in revenue highlights the company’s strong performance and its increasing market...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.